Brian Shields
Does the ivonescimab Mechanism of Action make sense to KOLs?
The release of the HARMONi-A and HARMONi-2 clinical trial data has led to significant excitement in the world of oncology and also finance. Both clinical trials focus on Chinese firm Akeso Biopharma's ivonescimab for the treatment of non-small cell lung cancer. Akeso's US partner Summit's stock has gone to the moon on the heels of these data releases at #ASCO24 and #WCLC24 Lung Cancer Sessions.
Many of the top key opinion leader in lung cancer across the globe have engaged in discussions regarding the releases of these data sets. Does the newly reported mechanism of action data answer all the questions regarding the ivonescimab mystery?
HARMONi-A and ivonescimab Social Discussion Leaders
Recently, Minhua Chua released a tweetorial discussing the preprint by Akeso Biopharma of the Mechanism of Action of ivonescimab.
Using the KOL Pulse AI Chatbot for HARMONi-A, I engaged in a chat to compare the tweetorial data to the KOL concerns about the HARMONi-A data set.
Here's how I started my discussion:
🙍PROMPT: please explain the harmoni-a trial results in the context of the newly reported mechanism of action.
🤖KOL Pulse AI Response:
Based on the tweets about the HARMONi-A trial results, here are the key findings and mechanism insights:
Trial Results:
- Primary endpoint PFS: 7.1 vs 4.8 months (HR 0.46, p<0.001)
- ORR: 50.6% vs 35.4% (p=0.006)
- OS: HR 0.72 (immature data with 30% maturity)
- CNS PFS benefit: HR 0.48
- Treatment discontinuation rate: 5.6%
Mechanism & Design:
- Ivonescimab is a tetravalent bispecific antibody targeting PD-1 and VEGF
- Key mechanistic findings:
- Forms stable "cluster" complex through synergistic binding
- VEGF presence increases PD-1 binding affinity 18-fold
- PD-1 presence enhances VEGF binding 4-fold
- Engineered Fc region (L234A/L235A mutations) reduces immune-related adverse events
- Reduced inflammatory cytokine release from HPMMs
Context:
- First successful PD-1/VEGF bispecific in EGFR-mutant setting post-TKI
- Differs from previous failed attempts with separate PD-1 and VEGF inhibitors (KEYNOTE-789, ORIENT-31)
- Currently approved in China with global expansion planned
Sources:
Wow, that was pretty good!
But I want more specific data. So I pressed for more specific feedback...
🙍PROMPT: please update your response with any doubts from physicians through their tweets
🤖KOL Pulse AI Response:
Here are the key physician doubts and discussions about HARMONi-A from the tweets:
Dr. Tejas Patil (@TejasPatilMD):
- Expresses confusion about results given previous negative trials
- Questions why PD1/VEGF bispecific shows benefit when KEYNOTE-789 (pembrolizumab) and ORIENT-31 (sintilimab+bevacizumab) did not show OS benefit Source
Dr. Charu Aggarwal (@CharuAggarwalMD):
- Raises concern about lack of CNS penetration Source
Dr. Nathan Pennell (@n8pennell):
- Suggests benefit may be purely from anti-VEGF effect rather than PD-1 activity
- Compares to bevacizumab's known PFS benefit with chemotherapy Source
Dr. Fernand Bteich (@fernandbteich):
- Questions what immunotherapy is adding beyond VEGF inhibition Source
Dr. Jordi Remon (@JordiRemon):
- Notes inconsistent benefit pattern across trials combining antiangiogenic + immunotherapy + chemotherapy
- Awaiting HARMONI-3 trial results in broader population Source
Check out the demo video of KOL Pulse AI in action:
How Does KOL Pulse AI Help Advance Science?
The integration of AI with verified scientific data sources enables comprehensive tracking of emerging clinical trial results. Here's how to leverage this tool effectively:
-
Real-Time Data Access
- Monitor tweets from leading oncologists like @StephenVLiu and @JackWestMD who share HARMONi-A trial updates
- Access peer-reviewed sources directly through embedded links.
-
Key Data Points Tracking
- Follow structured trial outcomes including:
- Primary endpoints (PFS HR 0.46)
- Secondary endpoints (OS HR 0.72)
- Safety profiles
- Subgroup analyses Source
-
Expert Commentary Integration
- Compare perspectives from multiple KOLs
- Track scientific discussions on mechanism of action
- Monitor real-world implementation insights Source
-
Data Verification
- Cross-reference against published abstracts (#ASCO24)
- Link to primary source documents
- Follow expert commentary threads for context
The KOL Pulse AI tool supports reliable scientific communication by:
- Maintaining data provenance
- Providing direct links to source material
- Enabling real-time expert discourse tracking
- Facilitating comprehensive trial result analysis
